Low-dose spironolactone ameliorates insulin resistance and suppresses elevated plasminogen activator inhibitor-1 during gestational testosterone exposure.
Arch Physiol Biochem
; 123(5): 286-292, 2017 Dec.
Article
em En
| MEDLINE
| ID: mdl-28480754
ABSTRACT
CONTEXT Elevated gestational circulating testosterone has been associated with pathological pregnancies that increase the risk of development of cardiometabolic disorder in later life. OBJECTIVE:
We hypothesised that gestational testosterone exposure, in late pregnancy, causes glucose deregulation and atherogenic dyslipidaemia that would be accompanied by high plasminogen activator inhibitor-1 (PAI-1). The study also hypothesise that low-dose spironolactone treatment would ameliorate these effects.METHODS:
Pregnant Wistar rats received vehicle, testosterone (0.5 mg/kg; sc), spironolactone (0.5 mg/kg, po) or testosterone and spironolactone daily between gestational days 15 and 19.RESULTS:
Gestational testosterone exposure led to increased HOMA-IR, circulating insulin, testosterone, 1-h post-load glucose, atherogenic dyslipidaemia, PLR, PAI-1 and MDA. However, all these effects, except that of circulating testosterone, were ameliorated by spironolactone.CONCLUSIONS:
These results demonstrate that low-dose spironolactone ameliorates glucose deregulation and atherogenic dyslipidaemia during elevated gestational testosterone exposure, at least in part, by suppressing elevated PAI-1.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Espironolactona
/
Testosterona
/
Resistência à Insulina
/
Inibidor 1 de Ativador de Plasminogênio
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article